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Abstract 23 
 24 
PDE4 cyclic nucleotide phosphodiesterases regulate cAMP abundance in cells and thereby 25 
regulate numerous processes, including cell growth and differentiation.  The rat PDE4A5 isoform 26 
(human homologue PDE4A4) interacts with the AIP protein (also called XAP2 or ARA-9).  27 
Germline mutations in AIP occur in approximately 20% of patients with Familial Isolated 28 
Pituitary Adenoma (FIPA) and 20% of childhood-onset simplex somatotroph adenomas.  We 29 
therefore examined the protein expression of PDE4A4 and the closely-related isoform PDE4A8 30 
in normal human pituitary tissue and in pituitary adenomas.   PDE4A4 had low expression in 31 
normal pituitary, but was significantly over-expressed in somatotroph, lactotroph, corticotroph 32 
and clinically non-functioning gonadotroph adenomas (P˂0.0001 for all subtypes).  Likewise, 33 
PDE4A8 was expressed in normal pituitary and was also significantly over-expressed in the 34 
adenoma subtypes (P˂0.0001 for all). Among the different adenoma subtypes, corticotroph and 35 
lactotroph  adenomas were the highest and lowest expressed for PDE4A4, respectively, whereas 36 
the opposite was observed for PDE4A8. Naturally occurring oncogenic variants in AIP were 37 
shown by a two-hybrid assay to disrupt the ability of AIP to interact with PDE4A5.  A reverse-38 
two-hybrid screen identified numerous additional variants in the TPR region of AIP that also 39 
disrupted its ability to interact with PDE4A5.  The expression of PDE4A4 and PDE4A8 in normal 40 
pituitary, their increased expression in adenomatous pituitary cells where AIP is meant to 41 
participate, and the disruption of the PDE4A4-AIP interaction by AIP mutants may play a role in 42 
pituitary tumorigenesis.     43 
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Introduction 44 
 45 
The PDE4 enzymes are members of a large superfamily of cyclic nucleotide 46 
phosphodiesterases (PDEs) that enzymatically break down the “second messengers” cAMP 47 
and/or cGMP and thereby regulate their abundance in cells (Francis et al. 2011, Bolger et al. 48 
2007).  cAMP signaling pathways, working through spatially-distinct sub-populations of the 49 
cAMP effectors, the cAMP-dependent protein kinase A (PKA) and the exchange protein 50 
activated by cAMP (Epac), differentially regulate a large range of distinct intracellular processes 51 
(Francis et al. 2011, Maurice et al. 2014). PDE4 enzymes are differentiated from other members 52 
of the PDE superfamily (PDE1 through PDE11, respectively), by their specificity for cAMP and by 53 
their ability to be inhibited by a class of highly-selective inhibitors.   54 
There are at least 20 different PDE4 isoforms in humans (Bolger 2007), which differ in 55 
their structure, pattern of expression in tissues, and interactions with specific proteins.  They are 56 
encoded by 4 genes (PDE4A, PDE4B, PDE4C and PDE4D), with additional diversity produced by 57 
alternative mRNA splicing and the use of promoters unique to each isoform (Bolger 2007, Bolger 58 
et al. 2007).  PDE4A5 (known as PDE4A4 in humans) is a well-studied PDE4 isoform that interacts 59 
with several proteins and has a number of characteristic biochemical properties (Bolger et al. 60 
1993, Bolger et al. 1994, Christian et al. 2010).   An important and apparently unique property of 61 
rat PDE4A5, compared to other rodent PDE4 isoforms, is that it interacts selectively with the AIP 62 
protein, a member of the immunophilin family of proteins (Bolger et al. 2003b).  The AIP protein 63 
interacts with PDE4A5 largely through its tetratricopeptide (TPR) domain (Bolger et al. 2003b, 64 
Igreja et al. 2010, Morgan et al. 2012), a well-characterized protein-interaction domain found on 65 
many proteins (Sikorski et al. 1990, Kinoshita et al. 1990) and which is often disrupted in 66 
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patients with AIP mutations (Igreja et al. 2010).  The interaction of AIP with PDE4A5 changes the 67 
enzymatic activity of PDE4A5 and also its ability to be inhibited by PDE4-selective inhibitors 68 
(Bolger et al. 2003b).    69 
Mutations in genes encoding components of cAMP pathways have been implicated in 70 
the predisposition to several endocrine neoplasms and related disorders (see ref. (Stratakis 71 
2013) for a review).  Germline mutations in the gene encoding the regulatory subunit type 1-α 72 
of PKA; (PRKAR1A) produce the multiple neoplasia, myxoma, and lentiginosis syndrome Carney 73 
complex (Horvath et al. 2010).  Germline mutations in the PKA catalytic subunit can produce 74 
adrenal cortical adenomas (PRKACA), (Beuschlein et al. 2014) or Carney Complex (PRKACB), 75 
(Forlino et al. 2014).  Mosaic somatic mutations in the gene encoding the G-protein alpha 76 
subunit (GNAS), which regulates adenylyl cyclase, the enzyme that synthesizes cAMP, cause 77 
McCune-Albright syndrome, characterized by fibrous dysplasia of bone, café-au-lait nodules and 78 
precocious puberty (Salpea & Stratakis 2014), while somatic mutations also can be detected in 79 
30-40% of somatotroph adenomas (Landis et al. 1989).  Recently, microduplications in the G-80 
protein-coupled orphan receptor GPR101, which activates adenylyl cyclase and thereby cAMP 81 
signaling, have been implicated in a disorder with very young-onset gigantism (Trivellin et al. 82 
2014).  These genetic syndromes implicate cAMP signaling in pituitary tumor pathogenesis and 83 
provide a rationale for study of additional cAMP signaling components in this process. 84 
Germline mutations in the AIP gene are present in approximately 20% of patients with 85 
familial isolated pituitary adenoma (FIPA).  The AIP-mutation-positive patients have a 86 
characteristic clinical phenotype with usually young- or childhood-onset growth hormone (GH) 87 
and/or prolactin (PRL)-secreting adenomas and can be seen in cases with no apparent family 88 
history as well (Vierimaa et al. 2006, Daly et al. 2007, Leontiou et al. 2008, Heliovaara et al. 89 
2009, Igreja et al. 2010, Gadelha et al. 2013, Beckers et al. 2013).  AIP is expressed in the 90 
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pituitary and many pathogenic AIP variants block its interaction with PDE4A5 (Vierimaa et al. 91 
2006, Leontiou et al. 2008, Igreja et al. 2010, Bolger et al. 2003b).   Furthermore, impaired 92 
function of AIP in the pituitary attenuates cAMP signaling (Formosa et al. 2013, Formosa & 93 
Vassallo 2014, Tuominen et al. 2015).   94 
Given the role of both cAMP signaling and AIP in the pathogenesis of pituitary tumors, 95 
we wished to explore further the potential role of the PDE4A5-AIP interaction in pituitary 96 
tumorigenesis.  Therefore, an important aim of the current studies was to demonstrate that 97 
PDE4A4 is expressed in normal pituitary and in pituitary adenomas, where it is available for 98 
interaction with AIP.   We had shown previously that mRNA encoding PDE4A4 and its rat/mouse 99 
orthologue, PDE4A5, is expressed in a number of tissues, including the brain (Bolger et al. 1994, 100 
Bolger et al. 1996), but there was no data on its expression in pituitary.   We have been 101 
particularly interested in the tissue-specific expression of PDE4A8, an isoform encoded by the 102 
PDE4A gene that has undergone rapid evolutionary change (Mackenzie et al. 2008).  Human 103 
PDE4A8 differs from its rodent counterpart almost exclusively at its alternatively-spliced amino-104 
terminus and related 5’ genomic sequences, which are likely to control its tissue expression 105 
(Mackenzie et al. 2008, Bolger et al. 1996).  Here we study PDE4A4 and PDE4A8 protein 106 
expression in normal pituitary and in pituitary adenomas using novel specific antibodies.  We 107 
also identify additional variants in AIP that affect its ability to interact with PDE4A5.  108 
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Materials and Methods 109 
 110 
Tissue Specimens 111 
Samples from pituitary adenomas were removed at transsphenoidal surgery.  The tumor type 112 
was determined on the basis of clinical and biochemical findings before surgery, and 113 
immunohistochemical determination of the expressed pituitary hormones: for the adenoma 114 
samples, all slides utilized showed more than 90% of the specific tumor, as confirmed by 115 
hematoxylin and eosin.  Autopsy pituitary samples were collected within 24 h of death from 116 
patients with no evidence of any endocrine abnormality. Consecutive cuts were prepared for 117 
histological analysis from normal pituitary tissue and different types of pituitary adenomas. . 118 
Informed consent was obtained from all pituitary patients, and the protocol was approved by 119 
the institutional Research Ethics Committee. 120 
 121 
PDE4 Antibodies 122 
The mouse monoclonal antibody 4A4-1, specific to human PDE4A4, was generated specifically 123 
for the present study against the peptide sequence SAERAERERQPHRPIERADA (Figure 1), 124 
corresponding to the unique amino-terminal region of PDE4A4 amino acids 51 through 70 in 125 
both human PDE4A4 (GenBank Accession number L20965.1) and rat PDE4A5 (GenBank 126 
L27057.1, Figure 1) (Bolger et al. 1993, Bolger et al. 1994, Mackenzie et al. 2008).  The rabbit 127 
polyclonal antibody 7233 specific to human PDE4A8 was described previously (Mackenzie et al. 128 
2008).  The mouse monoclonal antibody 4E1.16, specific for human PDE4A8, was generated to 129 
the same peptide as the polyclonal antibody, of the sequence KGDERSRETPESDRAN, 130 
corresponding to the unique amino-terminal region of PDE4A8 (GenBank AY593872, (Mackenzie 131 
et al. 2008)).  All monoclonal antibodies were purified by limiting dilution and then grown in 132 
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culture.  Antibodies were then purified from culture supernatants with a protein G-affinity 133 
matrix (Pierce-FisherThermo Scientific, USA). 134 
 135 
Immunoblotting 136 
COS7 cells were transfected with the plasmid pcDNAN46VSV to express human PDE4A4, or with 137 
pcDNA4A8VSV to express human PDE4A8, or with vector pcDNA3 (Life Technologies), using 138 
methods that we have described previously (McPhee et al. 1999, Mackenzie et al. 2008, 139 
Christian et al. 2010).  The proteins were engineered to contain a VSV epitope at their carboxy-140 
terminus.   Extracts from the cells were prepared using methods that we have described 141 
previously (McPhee et al. 1999, Mackenzie et al. 2008, Christian et al. 2010) and were analyzed 142 
by LDS-PAGE (Novex, USA) and immunoblotting with either an antibody to VSV (Sigma, USA; Ref. 143 
(Kreis 1986)) or the monoclonal antibody of interest.  For this purpose, samples were run in 144 
parallel lanes on the same gel and then transferred to a single filter.  For immunoblotting, the 145 
filter was then cut in half and each half incubated with the appropriate antibody; after washing, 146 
the two halves were re-joined for image generation with ECL, generating a single image with 147 
both antibodies.  Primary antibody incubations (1:500 for PDE4A4 and PDE4A8 and 1:5000 for 148 
VSV) were performed for 1 hour in Tris-buffered saline with 0.1% Tween-20, followed by 2 149 
washes in the same buffer.  Secondary antibody incubations (SC-5099, Santa Cruz 150 
Biotechnology, USA, 1:10,000) were performed in the same buffer, followed by 2 washes in the 151 
same buffer.  Signal development was with ECL (Pierce-ThermoFisher). 152 
 153 
Immunofluorescent Staining and Confocal Microscopy 154 
We performed confocal immunofluorescence analysis of somatotroph, corticotroph, lactotroph 155 
and clinically non-functioning gonadotroph adenomas as well as normal pituitary tissue. Normal 156 
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pituitary architecture was evaluated by reticulin staining. After deparaffinization and hydrating 157 
procedures, the slides were transferred into 400 mL of pre-warmed (94
o
C-96
o
C) target retrieval 158 
solution (Dako, California, USA, 40 ml of stock into 360 mL water) in a glass container in a water 159 
bath.  The sections were incubated in blocking solution (1% BSA and 0.1% Tween 20) at room 160 
temperature for 1 h and then incubated overnight at 4
o
C with one of the primary antibodies. 161 
The mouse monoclonal antibody 4A4-1 was used for all PDE4A4 comparisons while the mouse 162 
monoclonal 4E1.16 was used for all PDE4A8 comparisons.  In order to co-localize the selected 163 
proteins in different cells, polyclonal goat anti-GH (L20; 1:50, Santa Cruz, USA),  polyclonal goat 164 
anti-ACTH (P-12; 1:50, Santa Cruz, USA),  either polyclonal rabbit anti-FSH (87461:25, Abcam, 165 
USA) or polyclonal mouse anti-FSH (C10; 1:25 Dako, USA), and  polyclonal goat anti-PRL (C-17; 166 
1:50, Santa Cruz, USA) or polyclonal rabbit anti-prolactin (1:50; Dako, USA with one of the 167 
PDE4A4- or PDE4A8-specific antibodies described above, were also added to the incubation 168 
buffer. After an overnight incubation, slides were rinsed five times in PBS and then incubated for 169 
1h in the dark at room temperature with anti-goat Alexa 546 (1:100, Invitrogen, USA), anti-170 
rabbit Alexa 546 (1:50, 1:100 or 1:200, Invitrogen, USA), anti-mouse DyLight 488 (Pierce-171 
FisherThermo, 1:50, 1:200 or 1:400), anti-goat Alexa 488 (1:100, Invitrogen, USA) or anti-mouse 172 
Alexa 546 (1:200, Invitrogen, USA), , according to the primary antibodies previously used. Due to 173 
a change of PRL antibody used in our university hospital from goat to rabbit anti-PRL, secondary 174 
antibodies used in PRL experiments for the isoform PD4A8 had to be altered in order to reach 175 
the expected double labeling.  Following washes with PBS, sections were mounted in 90% 176 
glycerol/10% Tris 1M and images were captured through confocal microscope (Leica TCS SP5), 177 
63X objective, and 630X original magnification. All confocal settings were determined at the 178 
beginning of imaging session and remained unchanged. For quantitative analysis, images were 179 
captured at eight bits and analyzed in grey scale, using the protocol we have published 180 
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previously (Ribeiro-Oliveira, Jr. et al. 2008).  Briefly, three different normal pituitary samples and 181 
four to seven distinct samples of each adenoma subtype were analyzed. Three to four images 182 
were captured randomly from each sample and three measurements were obtained for each 183 
image, with about 30-50 cells also chosen randomly in each analyzed sample.  ImageJ (NIH, 184 
Bethesda, USA) software was used to quantify fluorescence intensity and area intensity, as well 185 
as area of each individual cell. The background fluorescence and the energy intensity threshold 186 
were s then subtracted from the region of interest in the same level for all examined pictures. 187 
The relative fluorescence corresponded to the unit ‘grey level’, varying from zero (black) to 255 188 
(white), as an average of the area for each cell (sum of grey value of all pixels divided by the 189 
number of pixels/area). 190 
 191 
Two-Hybrid Analysis of Protein-protein Interactions 192 
The effect of variants in AIP on its interaction with PDE4A5 was studied by the yeast-two-hybrid 193 
system, as described previously (Bolger et al. 2003b, Leontiou et al. 2008, Igreja et al. 2010).  For 194 
these studies, PDE4A5 was cloned into the NotI-site of pLEXAN, to generate a LexA DNA-binding-195 
domain fusion (i.e., the plasmid pLEXAR6).   Wild-type (WT) AIP and various missense AIP 196 
sequence variants were cloned into the NotI-site of pGADN, to generate GAL4 activation-domain 197 
fusions (i.e., the plasmid pGADNRB3 and mutants thereof).  Site-directed mutagenesis was 198 
performed using the circular mutagenesis method (Weiner et al. 1994) and all mutants were 199 
verified by sequencing before use. Quantitative β-galactosidase assays were performed in the 200 
Saccharomyces cerevisiae strain L40 by the method of Guarente (Guarente 1983) using O-201 
nitrophenyl-b-D-galactopyranoside as a substrate.  Each variant was tested in at least two 202 
different yeast clones. 203 
 204 
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“Reverse” Two-hybrid Analysis 205 
This was performed essentially as we have described previously, for a different interaction 206 
(Steele et al. 2001).   The plasmid pGADNRB3Sma was generated by site-directed mutagenesis of 207 
pGADNRB3.  It encodes the full open reading frame of AIP, cloned into the NotI site of pGADN 208 
(Bolger et al. 2003b), with a SmaI site engineered at codon 168.  The generation of this site 209 
created a variant (W168G) in AIP that had no effect on its ability to interact with PDE4A5 in two-210 
hybrid assays (data not shown).  To mutagenize the AIP TPR-homology region (Bolger et al. 211 
2003b), PCR primers were synthesized that amplified codons 168–330 of AIP, with some vector 212 
sequences at the 3' end of the insert. The PCR product overlapped approximately 30 nucleotides 213 
at each end with SmaI-cut pGADNRB3Sma DNA. Therefore, cotransformation of S. cerevisiae L40 214 
with the PCR product and SmaI-cut pGADNRB3Sma1 DNA efficiently generated full-length 215 
GADNRB3Sma with PCR-generated AIP TPRs, by the use of recombination in vivo. The PCRs were 216 
designed to introduce a single nucleotide substitution, on average, in the PCR product and used 217 
25 U/ml of Taq polymerase (ThermoFisher) in 20 mM Tris–HCl pH 8.4, 50 mM KCl, 5 mM MgCl2, 218 
0.2 mM dATP, 0.4 mM of each of dCTP, dTTP, and dGTP, 1 μg/ml of pGADNRB3Sma and each 219 
PCR primer at 1 nM/ml. Ten separate PCRs, each 100 μl, were performed for 25 cycles with an 220 
annealing temperature of 55°C.  The PCR products were pooled and 20 μl were mixed with 50 ng 221 
of SmaI-cut pGADNRB3Sma DNA and transformed into S. cerevisiae strain L40 containing 222 
pLEXAR6. Colonies containing both plasmids were selected by their ability to grow in the 223 
absence of tryptophan and leucine, replica-plated onto nylon filters, and subjected to a filter β-224 
galactosidase assay (Bolger 1998). The pGADNRB3Sma mutant plasmids were isolated from 225 
white colonies (i.e., those lacking β-galactosidase activity) by their ability to compliment the 226 
leuB-genotype of E. coli strain LB101. The PCR-generated region of the resulting plasmids was 227 
then sequenced with an ABI 3700 sequencer. 228 
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 229 
Characterization of AIP variants 230 
Three public databases were interrogated to check for the allele frequencies of the AIP variants 231 
tested in this study: the 1000 Genomes Project (Abecasis et al. 2012); the Exome Variant Server, 232 
NHLBI GO Exome Sequencing Project (ESP), Seattle, WA, USA (URL: 233 
http://evs.gs.washington.edu/EVS/) [date (March, 2016) accessed]; the Exome Aggregation 234 
Consortium (ExAC), Cambridge, MA, USA (URL: http://exac.broadinstitute.org, [accessed 1
st
 235 
March 2016]). 236 
 237 
Statistical Analysis 238 
Variables were first checked for normal distribution through the Shapiro-Wilk test.  The 239 
immunofluorescence data comparing each adenoma subtype to normal pituitary tissue were 240 
tested for statistical significance with the non-parametric Mann–Whitney test, using GraphPad 241 
Prism 6.0 (La Jolla, USA). Different adenoma subtypes were compared through Kruskal-Wallis 242 
followed by Dunn´s multiple comparisons test. Quantitative β-galactosidase assays were 243 
analyzed by unpaired t-test (SigmaPlot, Systat, San Diego, CA).  Significance was taken as P<0.05. 244 
Data are shown as means ± standard error or standard deviation.  245 
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Results 246 
 247 
PDE4A4 is specifically expressed in pituitary adenomas 248 
As the rodent homologue of PDE4A4 interacts with AIP (Bolger et al. 2003b), we wished to 249 
determine PDE4A4 distribution in normal human pituitary cells and adenomas (Figure 2).  For 250 
the present study, we developed a monoclonal antibody, 4A4-1, specific for PDE4A4 (and also 251 
PDE4A5). Immunoblotting of protein extracted from cells transfected with PDE4A4 shows a 252 
band with a relative molecular mobility of 125 ± 3 kDa, as shown previously (Mackenzie et al. 253 
2008).  Immunofluorescence of normal pituitary showed that PDE4A4 is present in GH and FSH 254 
cells, with very low expression in PRL or ACTH cells.  However, we detected a significantly higher 255 
expression of PDE4A4 in GH-, PRL- or ACTH-secreting pituitary adenomas, as well as FSH-positive 256 
NFPAs, compared to the corresponding cell type in normal pituitary (Figure 2).   In contrast, we 257 
did not see any expression in fat tissue, which was used here as a negative control.   258 
 259 
PDE4A8 is expressed in normal pituitary cells and adenomas 260 
We had previously developed a polyclonal antibody to PDE4A8 and used it to demonstrate its 261 
expression in several regions of the CNS (Mackenzie et al. 2008).  For the present study, we have 262 
developed a monoclonal antibody, 4E1.16, which has the same specificity as the polyclonal 263 
antibody (see Methods for details) and used immunofluorescence to determine its expression in 264 
pituitary tissue (Figure 3). The 4E1.16 antibody detected a protein of the correct size on 265 
immunoblotting of cells transfected to express PDE4A8.  Immunofluorescence of normal 266 
pituitary showed that PDE4A8 was present in all cell types, with somewhat lower expression in 267 
ACTH cells.  In pituitary adenomas, PDE4A8 was expressed at significantly higher levels, in all 268 
subtypes (Figure 3). We did not see any expression of PDE4A8 with this antibody in control 269 
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tissues, such as fat tissue, consistent with results obtained previously with the polyclonal 270 
antibody (Mackenzie et al. 2008).   271 
 272 
Differences among different adenoma subtypes for PDE4A4 and PDE4A8 273 
When different adenoma subtypes were compared for PDE4A4 (Figure 4A), this isoform was 274 
significantly reduced in prolactinomas compared to the other adenoma subtypes (Figure 4A). On 275 
the other hand, PDE4A4 abundance in corticotrophinomas was significantly increased as 276 
compared to the other adenoma subtypes (Figure 4A).  277 
For the PD4A8 isoform, in turn, prolactinomas showed significantly higher PD4A8 expression 278 
than the other adenoma subtypes (Figure 4B), while corticotrophinomas showed the lowest 279 
abundance of PD4A8 (Figure 4B). 280 
 281 
 Disease-associated variants in AIP attenuate its interaction with PDE4A5 282 
AIP interacts specifically with PDE4A5 (Bolger et al. 2003b) and mutations in AIP that are 283 
associated with FIPA attenuate this interaction (Leontiou et al. 2008, Igreja et al. 2010).   A yeast 284 
two-hybrid quantitative β-galactosidase assay can rapidly and conveniently assess the effects of 285 
AIP variants on its interaction with PDE4A5, which in turn can inform about the possible 286 
pathogenicity of AIP variants.  In the present study, we analyzed/re-analyzed a large number of 287 
disease-associated AIP variants, including six variants that we have not reported with this assay 288 
previously (Leontiou et al. 2008, Igreja et al. 2010), and found that attenuation of interaction 289 
generally correlated with the disease phenotype (Figure 5). The new and previously-studied 290 
single amino acid substitutions or deletions (C238Y, R271W, Y248del and V291M) and the 291 
truncation mutations (R81*, Q164*, Q217* and R304*), all of which are strongly disease-292 
associated, completely ablate the interaction (Figure 5). We also saw ablation, but with 293 
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borderline statistical significance, by the K241E and R304Q missense variants, which are also felt 294 
to be disease-associated.  The I257V and A299V variants, which are predicted to be unlikely to 295 
be pathogenic and have uncertain clinical significance, showed no clear difference.  Conversely, 296 
the R16H and V49M missense variants, which are generally considered to be rare SNPs (Igreja et 297 
al. 2010), and are located outside the TPRs, have no, or only a weak effect, on the interaction 298 
(Figure 5). Two apparently disease-causing variants, K103R and ΔG23/E24, have no clear 299 
inhibitory effect or may augment the interaction, as measured by this assay (Figure 5). K103R is, 300 
however, a conservative substitution and both K103R and ΔG23/E24 are located outside the 301 
TPRs, which are considered to mediate its interaction with PDE4A5.   302 
 303 
Isolation of additional variants in the AIP TPRs 304 
The AIP TPRs form a close association with two different regions of PDE4A5 (Bolger et al. 305 
2003b).  Given this close association, it seems unlikely that all the amino acids in the TPRs that 306 
are essential for this interaction have been identified in the analyses performed to date.  These 307 
amino acids would also be potential sites of disease-associated variants.  To identify such amino 308 
acids, we performed random mutagenesis of the AIP TPRs and then used two-hybrid approaches 309 
to select and identify variants that attenuated the AIP-PDE4A5 interaction.  This approach, 310 
typically called “reverse two-hybrid,” has successfully been used to characterize many protein-311 
protein interactions.  With this screen, we identified 7 single amino acid variants (K175E, C208R, 312 
N236H, C254R, H275L, L306P and L309P) and 1 double variant (W223R/V250A) in the AIP TPRs 313 
that strongly attenuated their ability to interact with PDE4A5 (Figure 5).  Intriguingly, one of 314 
these variants, C254R, has been recently identified as a disease-associated mutation in a patient 315 
with gigantism: this female patient was diagnosed at the age of 14 years due to tall stature (184 316 
cm, midparental height 161.5cm) and primary amenorrhoea and had a large (46x44x31 mm) 317 
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GH- and PRL-secreting macroadenoma causing hydrocephalus. IGF-1 was 5x and prolactin was 318 
150x upper limit of normal (Hernandez-Ramirez et al. 2015b, Iacovazzo et al. 2015).  319 
 Because of technical issues with the two-hybrid system, in that PDE4A8 tends to have 320 
intrinsic trans-activation activity, detectable in several different two-hybrid vector/host systems, 321 
we have been unable to assess the effects of AIP variants on its interaction, if any, with PDE4A8. 322 
Page 15 of 36
erc@bioscientifica.com
Manuscript submitted for review to Endocrine-Related Cancer
For Review Only
Bolger, et al. Page 16  
Discussion 323 
 324 
 PDE4s play an essential role in cAMP signaling in many organs and tissues (Maurice et al. 325 
2014, Francis et al. 2011, Conti & Beavo 2007, Houslay 2010, Bolger et al. 2007) in that they 326 
catalyze the breakdown of cAMP to AMP and thereby contribute to the regulation of cAMP 327 
levels in cells.  cAMP is generated by adenylyl cyclases, which, in majority of cell types, including 328 
pituitary, are regulated by several stimuli, including G protein-coupled receptors (GPCRs), 329 
calcium fluxes, and phosphorylation by a number of kinases (Willoughby & Cooper 2007).  cAMP 330 
activates two downstream effectors, PKA and Epac, and PKA phosphorylates numerous 331 
substrates, which in turn reflect its protean physiologic functions in cells.  GPCRs, cyclases, PKA 332 
and PDEs are often found to be physically co-localized in cells and thereby regulate cAMP levels 333 
in specific sub-cellular compartments (Maurice et al. 2014, Francis et al. 2011, Conti & Beavo 334 
2007, Houslay 2010, Bolger et al. 2007, Willoughby & Cooper 2007).    The presence and/or 335 
activity of PDE4 isoforms in these compartments may be regulated, at least in part, by specific 336 
protein-protein interactions; for example, the PDE4D5 isoform interacts selectively with RACK1 337 
and β-arrestin2 (Yarwood et al. 1999, Perry et al. 2002, Bolger et al. 2003a) and the PDE4A5 338 
isoform (called PDE4A4 in humans) selectively interacts with AIP (Bolger et al. 2003b).  The 339 
expression of cAMP signaling pathway components, including the PDE4s, varies substantially 340 
between tissues, thereby producing an additional level of specificity of action.  341 
Over-expression of WT AIP in rat GH3 and human HeLa cells was shown to reduce forskolin-342 
induced (but not basal) cAMP signaling (Formosa et al. 2013). This effect was observed even in 343 
the presence of the general PDE inhibitor IBMX or the selective PDE4 inhibitor rolipram, 344 
suggesting that the AIP–PDE interaction is either not required or only partially responsible for 345 
the reduction in forskolin-activated cAMP signaling by WT AIP. This may be explained by the fact 346 
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that AIP, in addition to PDE, interacts with several other proteins. Conversely, knock-down of 347 
endogenous AIP resulted in increased cAMP signalling even in basal conditions (Formosa et al. 348 
2013). Another mechanism suggested for AIP cAMP interaction s via the inhibitory G protein, G 349 
alpha-i2, as this inhibitory protein had lower level in AIP deficient cells and human samples 350 
suggesting that failure to inhibit cAMP synthesis through dysfunctional Galpha-i signaling 351 
underlies the development of GH-secreting pituitary adenomas in AIP mutation carriers. 352 
 353 
 In this study, we show that PDE4A4 and PDE4A8 proteins are expressed in human 354 
pituitary cells and that their expression is increased in all studied adenoma subtypes.  Although 355 
prior studies had demonstrated that mRNA transcripts from the PDE4A, PDE4B and PDE4D 356 
genes were present in pituitary cells and adenomas (Persani et al. 2001), these studies did not 357 
use immunohistochemistry or immunofluorescence to determine the precise cellular 358 
distribution of the isoforms.  Interestingly, although PDE4A4 and PDE4A8 are expressed in 359 
normal pituitary, they are expressed at higher levels in four different adenoma subtypes.  360 
Although the mechanistic effect(s) of this over-expression in adenomas will require further 361 
study, this level of PDE4 expression is highly likely to down-regulate cAMP signaling pathways 362 
and therefore be functionally important.  363 
Whereas differences in normal pituitary tissues obtained through consecutive cuts are expected 364 
due to the heterogeneous admixture of several different cell types, adenomas tend to be more 365 
uniform as they represent an expansion of a single neoplastic cell representing usually at least 366 
90% of the adenoma cells . Therefore we have compared the PDE isoform expression of the 367 
different pituitary adenoma subtypes. Whereas PDE4A4 was expressed lower in tumor prolactin 368 
cells and higher in tumor ACTH cells, the opposite was observed for PDE4A8 isoform.  While 369 
these observed results are quite of unknown origin, the differences between isoforms might be 370 
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related to the evolutionary change from one isoform to the other (Mackenzie et al. 2008). We 371 
note, that as we had to use a different secondary antibody for the prolactinomas for the PDE4A8 372 
staining, this  might have influenced the comparisons.  373 
 AIP mutations that predispose to adenomas also impair AIP’s ability to interact with 374 
PDE4A5 (Leontiou et al. 2008, Igreja et al. 2010).  However, AIP interacts with a number of 375 
proteins, including survivin and RET (Vargiolu et al. 2009, Kang et al. 2011), both important 376 
growth-regulatory proteins, with the aryl hydrocarbon receptor (Carver & Bradfield 1997), with 377 
cAMP signaling pathway members Gαi-2 and Gα1-3 (Tuominen et al. 2015) or PRKAR1A 378 
(Schemthaner-Reiter et al. 2014), as well as various chaperones, such as Hsp90 and Hsp70.  AIP 379 
has also been described as interacting with a different PDE, specifically PDE2A; however, the 380 
biochemical and physiologic implications of this observation remain uncertain (de Oliveira et al. 381 
2007, de Oliveira & Smolenski 2009).   Therefore, we need to explore further the potential role 382 
of the PDE4A4/5-AIP interaction in the pathog nesis of pituitary tumors.   It is possible that 383 
PDE4A4/5 in particular, in view of its selective interaction with AIP, plays an important role in 384 
AIP’s tumor suppressor effect; however, it is also possible that increased expression of PDE4 385 
isoforms could be a cellular response to the pro-proliferative effects of AIP loss in pituitary 386 
adenoma cells.  Finally, it is possible that PDE4A4/5 and other PDE4 isoforms play a role in 387 
pituitary processes other than adenoma formation. 388 
 Given that oncogenic mutations in AIP attenuate its interaction with PDE4A5, it is 389 
possible that PDE4A protein isoforms have important functional roles in pituitary and pituitary 390 
adenomas.  We have shown previously that AIP inhibits the enzymatic activity of PDE4A5 and 391 
therefore, acts to increase cAMP levels and thereby activate PKA.  Therefore, loss of AIP 392 
function should increase the activity of PDE4A4/5, lower cAMP levels and down-regulate PKA.  393 
Given that activation, rather than inactivation, of PKA predisposes to somatotroph adenomas 394 
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(see Introduction for details), it is most likely that the effect of the AIP mutants on PDE4A4/5 is 395 
to generate a compensatory response to tumorigenesis, rather than to promote tumorigenesis.  396 
AIP may support the function of inhibitory G-protein Gαi-2, (Tuominen et al. 2015) and lack of 397 
AIP lead to reduced Gαi-2 function, increased adenylyl cyclase activity, and therefore higher 398 
cAMP levels.  Overactivation of adenylyl cyclase due to gsp mutation, on the other hand, is 399 
known to produce over-expression of PDE4 as a possible compensatory process (Peverelli et al. 400 
2014).  Interaction of AIP and PDE4A4/5 may play a role in this process.  However, further 401 
functional experiments will be needed to assess this possibility. Interestingly, AIP mutations do 402 
not associate with gsp mutations in human adenomas (Hernandez-Ramirez et al. 2015a). 403 
 In this study, we assay a number of newly-identified AIP variants and show that almost 404 
all of them attenuate its interaction with PDE4A5.  This is consistent with these variants having 405 
an important effect on the biochemical activity of PDE4A5.  However, potential anomalies 406 
remain, in that two variants deemed pathogenic based on clinical data, K103R and ΔG23/E24, 407 
have no clear inhibitory effect or may augment the interaction, as measured by our assay.  408 
K103R is a conservative substitution and both K103R and ΔG23/E24 are located outside the 409 
TPRs, which are considered to mediate AIP protein’s interaction with PDE4A5.  It is possible that 410 
these mutations might destabilize the AIP protein generally in mammalian cells, as we have 411 
shown for several disease causing missense variants (Hernandez-Ramirez et al. 2015b) or have 412 
other effects on AIP and/or PDE4A4/5, that might not be detected by our assay.  Further 413 
functional studies might provide additional insights into the apparent aberrant effects of these 414 
mutants.    415 
Our study has several limitations. Although there is high homology between rat PDE4A5 and 416 
human PDE4A4, the human PDE4A4 protein has not been previously shown to interact with AIP. 417 
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The number of human samples assessed for these protein expression needs to be increased in 418 
the future.  419 
 In summary, our data suggest, to our knowledge for the first time, that PDE4A4 and 420 
PDE4A8 are expressed in normal human pituitary cells and are over-expressed in all studied 421 
pituitary adenoma subtypes. Differences among different adenoma subtypes for PDE4A4 and 422 
PDE4A8 isoforms might be related to the rapid evolutionary change from one isoform to the 423 
other.  We have also tested new AIP mutants for their ability to disrupt the PDE4A5-AIP 424 
interaction.  Our results suggest a number of further studies.  We have yet to evaluate the AIP 425 
content, and its correlation with PDE4 isoform expression, in normal and adenomatous 426 
pituitary.  Determining PDE4 expression in AIP-mutated tumors will possibly also shed light into 427 
this field.  The physiological function(s) and possible role of PDE4s in counteracting pituitary 428 
tumorigenesis require further investigation. 429 
  430 
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Table 1. Reported AIP variants tested in this study 431 
DNA change 
Protein 
change 
SNP id 
Control MAF 
- EVS 
Control MAF - 
ExAC 
Control MAF 
– 1000 
genomes 
c.47G>A p.R16H rs145047094 0.254 0.1956 0.1 
c.66_71del p.G23_E24del rs267606567 n.o. n.o. n.o. 
c.145G>A p.V49M rs1063385 0.0154 0.02395 n.o. 
c.241C>T p.R81* rs267606541 n.o. n.o. n.o. 
c.308A>G p.K103R rs267606548 n.o. n.o. n.o. 
c.490C>T p.Q164* rs104895073 n.o. n.o. n.o. 
c.649C>T p.Q217* rs267606566 n.o. n.o. n.o. 
c.713G>A p.C238Y rs267606569 n.o. 8.42e-04 n.o. 
c.721A>G p.K241E rs267606573 n.o. 4.212e-03 n.o. 
c.742_744del p.Y248del rs267606574 n.o. n.o. n.o. 
c.760T>C p.C254R n.a. n.o. n.o. n.o. 
c.769A>G p.I257V rs267606575 n.o. n.o. n.o. 
c.811C>T p.R271W rs267606579 n.o. n.o. n.o. 
c.871G>A p.V291M n.a. n.o. n.o. n.o. 
c.896C>T p.A299V rs148986773 0.1002 0.04275 n.a. 
c.910C>T p.R304* rs104894195 n.o. 1.715e-03 n.o. 
c.911G>A p.R304Q rs104894190 0.0693 0.1458 n.o. 
 432 
The allelic frequencies identified in controls in three public online databases (EVS, ExAC, and 433 
1000 genomes) are shown. MAF frequencies are expressed in %. MAF: minor allele frequency; 434 
n.o.: not observed.; n.a.: not applicable. 435 
  436 
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Figure legends 437 
Figure 1. Human PDE4A4 and rat PDE4A5, with AIP interaction sites  438 
Schematic representation of the human PDE4A4 protein structure. The human PDE4A4 consists 439 
of it’s a unique amino-terminal region, upstream conserved regions 1 and 2 (UCR1 and UCR2) 440 
separated by linker regions 1 and 2 (LR1 andLR2), a catalytic domain, and the unique carboxyl-441 
terminal region.  The domain structure of rat PDE4A5 is identical.  The amino acid sequences of 442 
the human PDE4A4 and rat PDE4A5 are shown of the specific regions implicated in the 443 
interaction of PDE4A5 with AIP: the unique N-terminal region and the EELD motif located at the 444 
beginning of UCR2. The middle row of amino acids show the high identity of these conserved 445 
regions between the two species. We marked the sequence with red letters 446 
SAERAERERQPHRPIERADA which was used to generate a new PDE4A5/PDE4A4 antibody. 447 
 448 
Figure 2.  Localization of PDE4A4 in pituitary   449 
A. Immunofluorescence with the 4A4-1 antibody in fat tissue, as a negative control. 450 
B. Immunoblotting with the 4A4-1 antibody. COS7 cells were transfected to express human 451 
PDE4A4 (4A4), or vector (Vect).  All PDE constructs also encoded a VSV epitope at the carboxyl-452 
terminus of the protein.  LDS-PAGE and immunoblotting with an antibody against VSV, or with 453 
4A4-1, were performed as described in Methods.  The PDE4A4 protein migrated at 97 kDa. 454 
C, D, E and F.  Double immunofluorescent staining using monoclonal 4A4-1 (green staining) and 455 
polyclonal GH, ACTH-, FSH, or PRL- (red staining) antibodies in normal pituitary (N=3), and in GH-456 
, ACTH-, FSH- (NFPA),  PRL-secreting adenomas (N=4-7 for each adenoma subtype; C, D, E and F, 457 
respectively).  The bar graphs to the right of each panel provide semi-quantitation of the relative 458 
fluorescence of PDE4A4 in each adenoma type, as compared to its respective normal cell.  Scale 459 
bar: 25µm. All data are shown as means ± S.E.M.; AU, arbitrary units; *P<0.0001.   460 
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 461 
Figure 3. Localization of PDE4A8 in pituitary 462 
A. Immunofluorescence with the 4E1.16 antibody in fat tissue, as a negative control. 463 
B. Immunoblotting with the 4E1.16 antibody. Extracts from COS7 cells transfected to express 464 
PDE4A8-VSV, or with vector (Vect) were immunoblotted with an antibody against VSV or with 465 
4E1.16.  On separate gels, PDE4A8-VSV extracts were immunoblotted with 4E1.16 and the 466 
peptide used as immunogen (P1), or an unrelated peptide (P2).  All methods were otherwise as 467 
for Figure 1B.  The PDE4A8 protein migrated at 102 kDa. 468 
C, D and E. Double immunofluorescent staining using monoclonal 4E1.16 (red staining) and 469 
polyclonal GH, ACTH, FSH (green staining) antibodies in normal pituitary (N=3) and GH-, ACTH-470 
secreting adenomas and NFPAs (N=4-7 for each adenoma subtype; C, D and E, respectively).  471 
F. Double immunofluorescent staining using monoclonal 4E1.16 (green staining) and polyclonal 472 
PRL (red staining) in normal pituitary (N=3) and PRL-secreting adenomas (N=5). The bar graphs 473 
to the right of each panel provide quantitation of the relative fluorescence of PDE4A8 in each 474 
adenoma type, compared to its respective normal cell.  Scale bar: 75µm.  All data are shown as 475 
means ± S.E.M.; AU, arbitrary units; *P<0.0001.     476 
 477 
Figure 4. Comparison of PDE4A4 and PDE4A8 immunostaining in pituitary adenomas  478 
A. PDE4A4 expression in pituitary adenoma subtypes. All data are shown as mean ± S.E.M.; 479 
AU, arbitrary units, *P<0.0001 compared to corticotroph adenomas , and 
●
P<0.0001 480 
compared to lactotroph adenomas  481 
B. PDE4A8 expression in pituitary adenoma subtypes. All data are shown as mean ± S.E.M.; 482 
AU, arbitrary units, *P<0.0001 compared to corticotroph adenomas , and 
●
P<0.0001 483 
compared to lactotroph adenomas 484 
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 485 
Figure 5. 486 
A. Yeast Two-hybrid Quantitative β-galactosidase Assay of Human AIP Mutants 487 
AIP mutants were expressed in yeast cells and their effect on AIP’s interaction with PDE4A5 was 488 
measured with a yeast two-hybrid quantitative β-galactosidase assay.  Variants not studied 489 
previously are indicated in bold type in this figure legend; selected previously-studied variants 490 
are included for comparison.  A significant reduction in β-galactosidase activity (0–30% of wild-491 
type [WT]; P˂0.03 by t-test) was observed for missense variants C238Y, R271W, V291M, and 492 
Y248del, as well as for all the truncation mutations tested (R81*, Q217*, Q164*, and R304*).  493 
The K241E and R304Q mutants were of borderline significance (P=0.062).   The R16H, V49M, 494 
K103R, I257V, and A299V variants show activity 33–100% of wild type (less than threefold 495 
difference; P=NS) from WT AIP.  Substantial increased activity is seen with the G23/E24 deletion 496 
(P=0.011).  Each variant was tested in at least two different yeast clones, with identical results 497 
(N=3 for each clone).  Mean ± SD are shown for each mutant.  Vector+4A5: PDE4A5 with the AD-498 
vector with no insert; Vectors X 2: both vectors with no insert. 499 
 500 
B. Yeast Two-hybrid Quantitative β-galactosidase Assay of AIP Mutants Identified in a Reverse 501 
Two-hybrid Screen 502 
AIP mutants identified in a reverse two-hybrid screen were expressed in yeast cells and their 503 
effect on AIP’s interaction with PDE4A5 was measured with a yeast two-hybrid quantitative β-504 
galactosidase assay, as in panel A.  All mutants showed a significant reduction in β-galactosidase 505 
activity (0–30% of wild-type [WT]; P˂0.03 by t-test).  Each variant was tested in at least two 506 
different yeast clones, with identical results (N=3 for each clone).  Mean ± SD are shown for each 507 
mutant.  Vector: PDE4A5 with the AD-vector with no insert.   508 
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